Literature DB >> 16936263

Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma.

Domenico Alvaro1, Barbara Barbaro, Antonio Franchitto, Paolo Onori, Shannon S Glaser, Gianfranco Alpini, Heather Francis, Luca Marucci, Paola Sterpetti, Stefano Ginanni-Corradini, Andrea Onetti Muda, David E Dostal, Adriano De Santis, Adolfo F Attili, Antonio Benedetti, Eugenio Gaudio.   

Abstract

We investigated the expression of estrogen receptors (ERs), insulin-like growth factor 1 (IGF-1), and IGF-1R (receptor) in human cholangiocarcinoma and cholangiocarcinoma cell lines (HuH-28, TFK-1, Mz-ChA-1), evaluating the role of estrogens and IGF-1 in the modulation of neoplastic cell growth. ER-alpha, ER-beta, IGF-1, and IGF-1R were expressed (immunohistochemistry) in all biopsies (18 of 18) of intrahepatic cholangiocarcinoma. ER-alpha was expressed (Western blot) only by the HuH-28 cell line (intrahepatic cholangiocarcinoma), whereas ER-beta, IGF-1, and IGF-1R were expressed in the three cell lines examined. In serum-deprived HuH-28 cells, serum readmission induced stimulation of cell proliferation that was inhibited by ER and IGF-1R antagonists. 17beta-Estradiol and IGF-1 stimulated proliferation of HuH-28 cells to a similar extent to that of MCF7 (breast cancer) but greater than that of TFK-1 and Mz-ChA-1, inhibiting apoptosis and exerting additive effects. These effects of 17beta-estradiol and IGF-1 were associated with enhanced protein expression of ER-alpha, phosphorylated (p)-ERK1/2 and pAKT but with decreased expression of ER-beta. Finally, transfection of IGF-1R anti-sense oligonucleotides in HuH-28 cells markedly decreased cell proliferation. In conclusion, human intrahepatic cholangiocarcinomas express receptors for estrogens and IGF-1, which cooperate in the modulation of cell growth and apoptosis. Modulation of ER and IGF-1R could represent a strategy for the management of cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936263      PMCID: PMC1698823          DOI: 10.2353/ajpath.2006.050464

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  Tamoxifen-mediated growth inhibition of human cholangiocarcinoma.

Authors:  L K Sampson; S M Vickers; W Ying; J O Phillips
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  An increasing incidence of cholangiocarcinoma: why?

Authors:  Laurie Blendis; Zamir Halpern
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

Review 3.  Estrogen receptors as targets for drug development for breast cancer, osteoporosis and cardiovascular diseases.

Authors:  Thresia Thomas; Michael A Gallo; T J Thomas
Journal:  Curr Cancer Drug Targets       Date:  2004-09       Impact factor: 3.428

4.  Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.

Authors:  S Saijyo; T Kudo; M Suzuki; Y Katayose; M Shinoda; T Muto; K Fukuhara; T Suzuki; S Matsuno
Journal:  Tohoku J Exp Med       Date:  1995-09       Impact factor: 1.848

5.  ER beta: identification and characterization of a novel human estrogen receptor.

Authors:  S Mosselman; J Polman; R Dijkema
Journal:  FEBS Lett       Date:  1996-08-19       Impact factor: 4.124

6.  A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I.

Authors:  M B Martin; T F Franke; G E Stoica; P Chambon; B S Katzenellenbogen; B A Stoica; M S McLemore; S E Olivo; A Stoica
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

7.  Biliary adenocarcinoma. Characterisation of three new human tumor cell lines.

Authors:  A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

8.  IGF-I and breast cancer: a meta-analysis.

Authors:  Runhua Shi; Herbert Yu; Jerry McLarty; Jonathan Glass
Journal:  Int J Cancer       Date:  2004-09-01       Impact factor: 7.396

9.  Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin.

Authors:  Beatriz del Río; Juana M García Pedrero; Carlos Martínez-Campa; Pedro Zuazua; Pedro S Lazo; Sofía Ramos
Journal:  J Biol Chem       Date:  2004-06-30       Impact factor: 5.157

Review 10.  Sex steroid hormones act as growth factors.

Authors:  A Migliaccio; G Castoria; M Di Domenico; A de Falco; A Bilancio; M Lombardi; D Bottero; L Varricchio; M Nanayakkara; A Rotondi; F Auricchio
Journal:  J Steroid Biochem Mol Biol       Date:  2002-12       Impact factor: 4.292

View more
  66 in total

1.  Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically.

Authors:  Antonio Franchitto; Alessia Torrice; Rossella Semeraro; Cristina Napoli; Gennaro Nuzzo; Felice Giuliante; Gianfranco Alpini; Guido Carpino; Pasquale Bartolomeo Berloco; Luciano Izzo; Antonio Bolognese; Paolo Onori; Anastasia Renzi; Alfredo Cantafora; Eugenio Gaudio; Domenico Alvaro
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 2.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 3.  Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Authors:  Michael Hopfner; Detlef Schuppan; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

4.  Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  J Hepatol       Date:  2008-05-22       Impact factor: 25.083

Review 5.  Cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ghulam Abbas; Keith D Lindor
Journal:  J Gastrointest Cancer       Date:  2009-08-25

6.  Ezrin-radixin-moesin-binding phosphoprotein (EBP50), an estrogen-inducible scaffold protein, contributes to biliary epithelial cell proliferation.

Authors:  Laura Fouassier; Peter Rosenberg; Martine Mergey; Bruno Saubaméa; Audrey Clapéron; Nils Kinnman; Nicolas Chignard; Gunilla Jacobsson-Ekman; Birgitta Strandvik; Colette Rey; Véronique Barbu; Rolf Hultcrantz; Chantal Housset
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

Review 7.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

8.  Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease.

Authors:  Domenico Alvaro; Paolo Onori; Gianfranco Alpini; Antonio Franchitto; Douglas M Jefferson; Alessia Torrice; Vincenzo Cardinale; Fabrizio Stefanelli; Maria Grazia Mancino; Mario Strazzabosco; Mario Angelico; Adolfo Attili; Eugenio Gaudio
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

9.  Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease.

Authors:  Paolo Onori; Romina Mancinelli; Antonio Franchitto; Guido Carpino; Anastasia Renzi; Stefania Brozzetti; Julie Venter; Heather Francis; Shannon Glaser; Douglas M Jefferson; Gianfranco Alpini; Eugenio Gaudio
Journal:  Liver Int       Date:  2013-04-25       Impact factor: 5.828

10.  Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.

Authors:  Ling Xu; Martin Hausmann; Wolfgang Dietmaier; Silvia Kellermeier; Theresa Pesch; Manuela Stieber-Gunckel; Elisabeth Lippert; Frank Klebl; Gerhard Rogler
Journal:  BMC Cancer       Date:  2010-06-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.